SCHEMBL6483258

SCHEMBL6483258

CC(=O)C1=C(O)C(=O)N(c2ccc(Br)cn2)C1c1ccc(Br)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 1.00
MAPT P10636 3/20 1.00
RXFP1 Q9HBX9 7/20 0.87
ALDH1A1 P00352 3/20 0.87
NPC1 O15118 1/20 0.87
RAB9A P51151 1/20 0.87
NPSR1 Q6W5P4 2/20 0.83
GAA P10253 2/20 0.73
HIF1A Q16665 2/20 0.73
ATM Q13315 1/20 0.68
MEN1 O00255 7/20 0.67
KMT2A Q03164 7/20 0.67
HPGD P15428 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
CCR1 P32246 2/20 0.62
CCR2 P41597 1/20 0.62
ALOX15 P16050 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13662472 0.92 MAPT (0.84) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL6781571 0.81 RXFP1 (1.00) KDM4EMAPTRXFP1ALDH1A1ATM
SCHEMBL12540328 0.77 KDM4E (1.00) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL6778710 0.77 CCR1 (1.00) KDM4EMAPTRXFP1ALDH1A1ATM
SCHEMBL14563954 0.76 RXFP1 (0.87) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL1943153 0.75 RXFP1 (0.76) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL8776183 0.72 MAPT (0.57) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL6720980 0.71 MEN1 (0.70) KDM4EMAPTRXFP1ALDH1A1NPSR1
SCHEMBL5597999 0.71 RXFP1 (0.58) KDM4EMAPTRXFP1ALDH1A1NPC1
SCHEMBL8776238 0.70 MAPT (0.54) KDM4EMAPTRXFP1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936633-B2 Pyrrolidinone derivatives UCB S.A. (BE) 2005-08-30 US claimed
US-20040157914-A1 Pyrrolidinone derivatives UCB, S.A. 2004-08-12 US claimed
US-6727275-B2 ANTIINFLAMMATORY, ANTIALLERGEN, AND ANTIASTHMATIC AGENTS UCB, S.A./N.V. (BE) 2004-04-27 US claimed
EP-2089383-B1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2015-09-16 EP disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 WO disclosed
US-6936633-B2 Pyrrolidinone derivatives UCB S.A. (BE) 2005-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157914-A1 Pyrrolidinone derivatives CCR2, CCR1, CCL2 KDM4E 2561/4885MAPT 2829/4885RXFP1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.